NervGen Pharma readies trials for biologic treatment of spinal cord injury, multiple sclerosis

Alan Condon -   Print  |

NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients.

Four things to know:

1. NVG-291 is a linear peptide comprised of common amino acids.

2. Its Phase 1 safety and pharmacokinetic study in healthy subjects will begin in the first quarter of 2020.

3. The expansion of its Phase 1 trial on spinal cord injury patients will begin in the second half of 2020.

4. A Phase 2 multiple sclerosis trial is set for the first quarter of 2021.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers